Literature DB >> 32410877

Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic.

Davide Mauri1, Konstantinos Kamposioras2, Maria Tolia3, Filippo Alongi4, Dimitrios Tzachanis5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32410877      PMCID: PMC7220173          DOI: 10.1016/S1470-2045(20)30278-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
Patients with cancer are at high risk for serious illness and death from COVID-19. The pandemic has altered the routine for oncology patients. Their lives depend on their ability to receive medical care, but every visit to a health-care facility exposes them to the risk of contracting the virus; therefore, concerns about getting infected might interfere with their continuity of care. Does oncology treatment outweigh the risk of infection? The psychological pressure of uncertainty for patients with cancer is particularly high. In this difficult phase, these patients need guidance and support. Professional guidance becomes of extreme importance for reducing the risk of contracting the virus, promoting patients' safety, treatment, and compliance, and ameliorating patients' stress. Several medical centres and national and international oncology societies are attempting to provide guidance to patients, but their extent and content vary; some national oncology societies have not provided any recommendations at all. We have developed an international scientific panel with the aim to review available guidelines from 63 oncology societies (appendix p 2) and provide summarised comprehensive recommendations for patients with cancer. 29 of 63 oncology societies provided some form of guidance for patients, either as their own recommendation statements or as a link to guidance from other societies (we only considered links to guidelines written in the society's native language). As most patients worldwide do not speak English, the language of guidance delivery is a major barrier to the dissemination of recommendations in different countries (figure ). Therefore, we have translated the summary of the comprehensive recommendations into 22 languages (Arabic, Bulgarian, Catalan, Chinese, Croatian, Czech, Dutch, English, French, German, Greek, Hungarian, Italian, Japanese, Norwegian, Polish, Portuguese, Romanian, Serbian, Slovenian, Spanish, and Swedish). The text and translations can be found at the European Cancer Patients Coalition and Hellenic Cancer Federation websites. We are working on a translation into Urdu. 48 physicians from 27 countries voluntarily participated in the working panel.
Figure

Number of people (in millions) whose native language is in the top 23 most spoken worldwide

(A) Comparison of the number of English speakers (green) with speakers of the remaining 22 languages; the proportion of English speakers is 8%. (B) Number of people whose native language is covered by our multilanguage translation (green); the proportion of people able to access guidelines in their native language is 68%.

Number of people (in millions) whose native language is in the top 23 most spoken worldwide (A) Comparison of the number of English speakers (green) with speakers of the remaining 22 languages; the proportion of English speakers is 8%. (B) Number of people whose native language is covered by our multilanguage translation (green); the proportion of people able to access guidelines in their native language is 68%. Our panel identified six main areas of recommendations. The English version of the guidance with references is presented in the appendix (pp 4–26). The first area concerns general considerations for patients with cancer during the COVID-19 pandemic (appendix p 4). Patients with cancer are at higher risk for infection, admission to the intensive care unit, and death. This high risk is related to the immunosuppression caused by a variety of factors, such as the disease itself, low performance status, cachexia, and the effect of treatments (surgery, chemotherapy, corticosteroids, radiotherapy, and bone marrow transplantation). The degree of immunosuppression depends on the type of cancer, the patient's age, fitness, comorbidities, the type of therapy, and the time since last therapy. Patients with haematological malignancies, especially those who received bone marrow transplants recently, are at particularly high risk. Patients with cancer are encouraged to ask their physicians about their individual risk. COVID-19 symptoms appear 2–14 days after exposure and include fever, cough, runny nose, sore throat, body aches, diarrhoea, and loss of smell or taste. Immediate medical attention should be sought for more severe symptoms, such as high fever, difficulty breathing, chest pain, confusion, and blue lips or face. Patients with cancer should have a low threshold for seeking medical attention if they have any new symptoms. The second area of recommendation regards specific protocols or any special measure that people with cancer should take to avoid COVID-19 infection (appendix p 6). The best way to prevent infection is to avoid exposure to the virus by implementing strict hygienic and behavioural measures. Patients with cancer and household members should follow these measures more strictly given their high risk of infection. Cancer survivors might not be at such high risk but should contact their physician to find out more about their individual risk. Hygienic measures include frequent hand washing, disinfecting objects, avoiding handling objects in public places, and washing fruits and vegetables. Behavioural modifications include staying at home, not gathering in public places, and not touching other people. Travel, non-essential home visitors, the use of public transport, and the purchase of unpackaged food should be avoided. The use of a face mask is recommended, at least in crowded places, but not as a replacement for other established preventive measures. It should be worn when visiting a cancer centre or hospital. The third area of recommendation reflects on what to do if someone is symptomatic, and indicates to patients whether there are any vaccines, treatment, or dietary or other supplementations that are effective against COVID-19 infection (appendix p 9). Patients with cancer should avoid people with a known exposure, infected asymptomatic people, and infected symptomatic people for at least 14 days and until their symptoms have resolved. If a patient with cancer experiences new cold-like symptoms, they should contact their oncologist and remain strictly quarantined. Currently, there are no vaccines or drugs that have been proven to treat or prevent COVID-19. There is no evidence that dietary interventions, complementary and alternative medicines, or supplements can treat or prevent COVID-19. The fourth area of recommendation is related to mental health: guidance on managing anxiety and stress (appendix p 11). Patients with cancer are encouraged to live as healthily as they can. Some recommendations include breathing fresh air, engaging in physical exercise and creative activities, and having quality time with their families. Rest, sleep, and healthy eating are important. Patients' levels of stress and anxiety are generally high during a pandemic, especially because they are already dealing with cancer. Some suggestions to counteract these negative feelings include communication with friends and family, engaging in pleasant activities, meditation, yoga and physical exercise, eating healthily, avoiding excessive exposure to the news, and following good sleep hygiene. Patients who feel that they cannot cope with their stress should talk to their doctor. Building trust between physicians and patients to enhance patients' confidence in medical staff decisions and improve their compliance with medical advice is important, and is the fifth area of recommendation (appendix p 13). The main goal of the medical team is to keep patients safe from COVID-19 while retaining the highest quality of care for their cancer. Patients should trust their physicians regarding deviations from their usual care. Treatment for infected or exposed patients might be deferred by 14 days or longer. For all patients with cancer, the possibilities of delaying or holding treatment are being evaluated on a case-by-case basis, according to the overall clinical picture, the aggressiveness of the cancer, and the potential health risks from COVID-19. During the acute phase of the pandemic, preventive care, elective procedures, some chemotherapy treatments, and supportive treatments are being postponed. Many visits are being converted to telephone or video visits. Cancer centres are altering the routines that patients are used to. It is important that patients remain confident that their oncology teams are there to support them. Patients need to be aware that a lot of misleading information circulates on the internet. The best sources of safe information online can be found on official websites provided by medical centres, oncology societies, and governments. Finally, the sixth area of recommendation concerns the procedures at cancer centres (appendix p 16). Patients and visitors who have symptoms or have been exposed to an infected person should not visit their cancer centre, but should first call their doctor's office for further instruction. Symptomatic patients who arrive at the hospital should wear a face mask and report their symptoms upon arrival. All patients should keep a safe distance from other individuals. Not more than one visitor should accompany the patient. Patients and visitors must wash their hands upon entering and leaving the centre. At the hospital, patients with known or suspected COVID-19 are being kept in separate wards, and no visitors are allowed. For patients without COVID-19, only one visitor is allowed (or none in some places). Patients with cancer need to think about their goals of care in advance and discuss them with their loved ones and physicians. There is no evidence that COVID-19 is transmittable by blood. Blood donors are encouraged to continue donating unless they have new symptoms or a possible exposure to COVID-19. Patients with cancer are facing unprecedented circumstances. We believe that a summary of recommendations from different oncology societies across the globe and their multilanguage translation will provide useful guidance to patients and caregivers.
  14 in total

Review 1.  Cancer or COVID-19? A Review of Guidelines for Safe Cancer Care in the Wake of the Pandemic.

Authors:  Manit K Gundavda; Kaival K Gundavda
Journal:  SN Compr Clin Med       Date:  2020-11-21

Review 2.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

3.  Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic.

Authors:  Laura M Spring; Michelle C Specht; Rachel B Jimenez; Steven J Isakoff; Gary X Wang; Amy Ly; Jennifer A Shin; Aditya Bardia; Beverly Moy
Journal:  N Engl J Med       Date:  2020-07-01       Impact factor: 91.245

Review 4.  Upper Gastrointestinal Cancer Management in the COVID-19 Era: Risk of Infection, Adapted Role of Endoscopy, and Potential Treatment Algorithm Alterations.

Authors:  Konstantinos Apostolou; Stamatina Vogli; Maximos Frountzas; Athanasios Syllaios; Maria Tolia; Ioannis S Papanikolaou; Dimitrios Schizas
Journal:  J Gastrointest Cancer       Date:  2020-11-26

Review 5.  Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth.

Authors:  Konstantinos Kamposioras; Davide Mauri; Konstantinos Papadimitriou; Alan Anthoney; Nadia Hindi; Branka Petricevic; Mario Dambrosio; Antonis Valachis; Pantelis Kountourakis; Jindrich Kopecky; Cvetka Grašič Kuhar; Lazar Popovic; Nataliya P Chilingirova; George Zarkavelis; Ramon Andrade de Mello; Natalija Dedić Plavetić; Christos Christopoulos; Bianca Mostert; John R Goffin; Dimitiros Tzachanis; Haytham Hamed Saraireh; Fei Ma; Ida Pavese; Maria Tolia
Journal:  Front Oncol       Date:  2020-11-19       Impact factor: 6.244

6.  The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study.

Authors:  Giuseppe Deledda; Niccolò Riccardi; Stefania Gori; Sara Poli; Matteo Giansante; Eleonora Geccherle; Cristina Mazzi; Ronaldo Silva; Nicoletta Desantis; Ambra Mara Giovannetti; Alessandra Solari; Paolo Confalonieri; Licia Grazzi; Elena Sarcletti; Gabriella Biffa; Antonio Di Biagio; Carlo Sestito; Roland Keim; Alida M R Di Gangi Hermis; Mariantonietta Mazzoldi; Alessandro Failo; Anna Scaglione; Naida Faldetta; Patrizia Dorangricchia; Maria Moschetto; Hector Josè Soto Parra; Jennifer Faietti; Anna Di Profio; Stefano Rusconi; Andrea Giacomelli; Fabio Marchioretto; Filippo Alongi; Antonio Marchetta; Giulio Molon; Zeno Bisoffi; Andrea Angheben
Journal:  Int J Environ Res Public Health       Date:  2021-01-05       Impact factor: 3.390

7.  Experiences of people affected by cancer during the outbreak of the COVID-19 pandemic: an exploratory qualitative analysis of public online forums.

Authors:  Sara Colomer-Lahiguera; Karin Ribi; Hayley J Dunnack; Mary E Cooley; Marilyn J Hammer; Christine Miaskowski; Manuela Eicher
Journal:  Support Care Cancer       Date:  2021-02-11       Impact factor: 3.603

8.  Time to Treatment Initiation for Breast Cancer During the 2020 COVID-19 Pandemic.

Authors:  Kathryn Hawrot; Lawrence N Shulman; Ira J Bleiweiss; Elizabeth J Wilkie; Zachary A K Frosch; Rachel C Jankowitz; Amy I Laughlin
Journal:  JCO Oncol Pract       Date:  2021-03-12

9.  Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.

Authors:  Begoña de Las Heras; Kamal S Saini; Frances Boyle; Felipe Ades; Evandro de Azambuja; Ivana Bozovic-Spasojevic; Marco Romano; Marta Capelan; Rajeev Prasad; Pugazhenthi Pattu; Christophe Massard; Chia Portera; Monika Lamba Saini; Brajendra Prasad Singh; Ramachandran Venkitaraman; Richard McNally; Manuela Leone; Enrique Grande; Sudeep Gupta
Journal:  Oncol Ther       Date:  2020-08-04

10.  Oncological care organisation during COVID-19 outbreak.

Authors:  Concetta Elisa Onesti; Hope S Rugo; Daniele Generali; Marc Peeters; Khalil Zaman; Hans Wildiers; Nadia Harbeck; Miguel Martin; Massimo Cristofanilli; Javier Cortes; Vivianne Tjan-Heijnen; Sara A Hurvitz; Guy Berchem; Marco Tagliamento; Mario Campone; Rupert Bartsch; Sabino De Placido; Fabio Puglisi; Sylvie Rottey; Volkmar Müller; Thomas Ruhstaller; Jean-Pascal Machiels; PierFranco Conte; Ahmad Awada; Guy Jerusalem
Journal:  ESMO Open       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.